Cargando…
CDK8-Novel Therapeutic Opportunities
Improvements in cancer therapy frequently stem from the development of new small-molecule inhibitors, paralleled by the identification of biomarkers that can predict the treatment response. Recent evidence supports the idea that cyclin-dependent kinase 8 (CDK8) may represent a potential drug target...
Autores principales: | Menzl, Ingeborg, Witalisz-Siepracka, Agnieszka, Sexl, Veronika |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6630639/ https://www.ncbi.nlm.nih.gov/pubmed/31248103 http://dx.doi.org/10.3390/ph12020092 |
Ejemplares similares
-
Triple-negative breast cancer cells rely on kinase-independent functions of CDK8 to evade NK-cell-mediated tumor surveillance
por: Knab, Vanessa Maria, et al.
Publicado: (2021) -
Untwining Anti-Tumor and Immunosuppressive Effects of JAK Inhibitors—A Strategy for Hematological Malignancies?
por: Klein, Klara, et al.
Publicado: (2021) -
T Cell-Intrinsic CDK6 Is Dispensable for Anti-Viral and Anti-Tumor Responses In Vivo
por: Klein, Klara, et al.
Publicado: (2021) -
Loss of NKG2D in murine NK cells leads to increased perforin production upon long‐term stimulation with IL‐2
por: Prinz, Daniela, et al.
Publicado: (2020) -
Loss of JAK1 Drives Innate Immune Deficiency
por: Witalisz-Siepracka, Agnieszka, et al.
Publicado: (2019)